Shots:

• The P-I CRB-402 study involves assessing of bb21217 as an investigational anti- BCMA CAR T (150 x 10⁶) cell therapy in patients with r/r multiple myeloma
• The study demonstrated 83% of total patients (N=12) achieved an objective clinical response; CR 3- VGPR 2; 4 PR; with no death occurred
• bb21217 is an anti-BCMA CAR T cell therapy targeted to kill plasma & myeloma cells expressing B cell maturation antigen (BCMA) and is jointly developed by Bluebird Bio and Celgene

Ref: Bluebird Bio | Image: Wral Techwire